Insight: New doubts about prostate-cancer vaccine Provenge

NEW YORK (Reuters) Prostate cancer vaccine Provenge has prolonged incited passions distinct any other cancer therapy.
Doctors who lifted doubts about it perceived genocide threats. Health regulators and lawmakers faced shrill protests during their offices. A medicine during a American Cancer Society was so intimidated by Provenge partisans that he yanked a doubtful contention of it from his blog.
The vitriol dissolute in Apr 2010, when a U.S. Food and Drug Administration authorized Provenge for modernized prostate cancer, gratifying investors in manufacturer Dendreon and patients who for years had demanded it be put on a market.
But a bell on Round Two sounded when Marie Huber, a lerned scientist and former hedge-fund analyst, done it her goal in a final year to investigate what she believes are lethal flaws in a studies that led to a capitulation of Provenge by a FDA.
She argues that a categorical reason Provenge seemed to ex...